Health Catalyst Stock Price, News & Analysis

Health Catalyst (NASDAQ: HCAT) reported its Q1 2025 financial results with total revenue of $79.4 million, representing a 6% year-over-year growth, and Adjusted EBITDA of $6.3 million, marking an 86% increase from the previous year. The company successfully added 10 net new Platform Clients in Q1 2025, positioning them well to achieve their target of 40 net new Platform Client additions for the year.

The company's financial metrics showed mixed results, with gross margin declining to 36% from 39% year-over-year, and net loss increasing to $23.7 million. For Q2 2025, Health Catalyst expects revenue of approximately $80.5 million and Adjusted EBITDA of $8 million. The full-year 2025 guidance projects total revenue of $335 million, including technology revenue of $220 million, and Adjusted EBITDA of $41 million.

Health Catalyst and Microsoft have announced a strategic partnership to accelerate AI adoption in healthcare organizations. The collaboration leverages Health Catalyst's expertise with Microsoft Azure and Azure AI Foundry to deliver advanced AI solutions for improved operational, clinical, and financial performance.

Two key solutions - Healthcare.AI™ and Health Catalyst Ignite™ - are immediately available on the Azure Marketplace, with more solutions planned for future release. These tools aim to address challenges in data analytics, cybersecurity, financial, and operational improvement.

The partnership combines Microsoft's AI technology with Health Catalyst's healthcare improvement expertise to deliver sustainable performance improvements for healthcare organizations of all sizes. Leadership from both companies emphasize that successful AI implementation requires both powerful technology and deep healthcare industry knowledge.

Health Catalyst (Nasdaq: HCAT) has scheduled its first quarter 2025 operating results announcement for Wednesday, May 7, 2025, after market close. The healthcare data and analytics technology provider will host a conference call at 5:00 pm ET on the same day to discuss the results.

U.S. participants can join the call by dialing 800-343-5172, while international participants should dial 203-518-9856, using conference ID 'HCATQ125'. A live audio webcast will be accessible at ir.healthcatalyst.com, with a replay available for approximately 90 days after the call.

Health Catalyst (HCAT) has launched Health Catalyst Ignite Spark™, a specialized data and analytics solution targeting community health systems, regional hospitals, and multi-site practices. The platform is designed to help smaller healthcare organizations facing challenges of shrinking margins and resource constraints.

The solution offers key features including:

• Data integration and normalization from multiple sources
• Centralized governance
• Self-service access to actionable insights
• AI-driven decision-making capabilities
• Reduced IT burden and costs

Ignite Spark aims to break down cost, access, and expertise barriers for regional hospital networks, primary care networks, urgent care centers, and specialty practices, enabling data-driven improvements in clinical operations, revenue performance, and cost control.

Health Catalyst (HCAT) has announced a stock repurchase of approximately $5 million, executed between March 3-10, 2025. The company retired approximately 1.1 million shares of common stock as part of its existing share repurchase program, which was authorized in August 2022 with a total capacity of $40 million.

CEO Dan Burton stated that the repurchase reflects the company's confidence in its future, citing that current market prices don't reflect their long-term value. The company anticipates continued achievement of operating leverage and revenue growth reacceleration, emphasizing their commitment to creating sustainable value for shareholders, clients, and team members.

Health Catalyst (Nasdaq: HCAT) has entered into a multi-year agreement with Signature Healthcare, an integrated healthcare delivery system in Southeastern Massachusetts. The partnership centers on implementing Health Catalyst Ignite™, a modern data and analytics ecosystem that integrates clinical and claims data while enhancing care coordination.

The solution will enable Signature Healthcare to leverage data insights for supporting quality patient outcomes and optimizing operational performance. The platform integrates best-in-class cross-industry technologies with healthcare-specific data models and self-service tools in a scalable environment.

Robert Haffey, Signature Healthcare's President and CEO, emphasized the alignment between Health Catalyst's solutions and their leadership team's governance objectives. The partnership aims to enhance patient health and wellness while supporting operational excellence, with Health Catalyst providing population health expertise to maximize Ignite's capabilities.

Health Catalyst (HCAT) reported strong financial results for Q4 and full-year 2024, achieving total revenue of $307 million and Adjusted EBITDA of $26 million for 2024. The Technology segment showed notable performance with revenue of $195 million for full-year 2024 and $52 million for Q4 2024, representing 10% year-over-year growth.

The company provided guidance for 2025, projecting total revenue of approximately $335 million, Technology revenue of $220 million, and raised their Adjusted EBITDA target by $2 million to $41 million. For Q1 2025, they expect revenue of approximately $79 million and Adjusted EBITDA of $4 million.

The company announced governance updates, including the appointment of Dr. Jill Hoggard Green to the Board of Directors and the promotion of Dr. Daniel Samarov to Chief AI Officer.

Health Catalyst (HCAT), a leading healthcare data and analytics technology provider, has announced its participation in the Raymond James & Associates' 46th Annual Institutional Investors Conference in Orlando, FL. The company's executive team, including CEO Dan Burton, CFO Jason Alger, COO Dan LeSueur, and VP of Investor Relations Jack Knight, will conduct a fireside chat presentation on Tuesday, March 4, 2025, at 1:40 p.m. ET.

Interested parties can access the webcast through Health Catalyst's investor relations website at https://ir.healthcatalyst.com.

Health Catalyst (HCAT) has announced it will release its fourth quarter and full year 2024 operating results on Wednesday, February 26, 2025, after market close. The company will host a conference call at 5:00 pm ET on the same day to review the results. U.S. participants can join by dialing 800-343-5172, while international participants can dial 203-518-9856, using conference ID 'HCATQ424'. A live audio webcast will be available at ir.healthcatalyst.com, with a replay accessible for approximately 90 days after the call.